TITLE

Optimizing functional imaging protocols for assessing the outcome of fetal cell transplantation in Parkinson's disease

AUTHOR(S)
Politis, Marios
PUB. DATE
January 2011
SOURCE
BMC Medicine;2011, Vol. 9 Issue 1, p50
SOURCE TYPE
Academic Journal
DOC. TYPE
Article
ABSTRACT
Clinical trials aiming to assess the safety and efficacy of fetal cell transplantation in Parkinson's disease rely on the hypothesis that the grafted tissue will survive and grow, restore striatal dopaminergic neurotransmission, improve the connectivity between striatum, thalamus and cortex and, thereby, produce long-lasting clinical improvement while avoiding the development of adverse effects. Although transplantation of human fetal ventral mesencephalic tissue has been reported as one of the most effective reparative therapies in Parkinson's disease patients to date, different studies have shown inconsistent results causing a paucity of new trials over the last decade. However, during this period, functional imaging alongside other scientific developments from clinical observations and animal work has significantly aided in understanding the mechanisms responsible for the success or failure of grafting human fetal tissue. Recent advances in functional imaging including both positron emission tomography and functional magnetic resonance imaging could be proven useful in vivo tools for the development and assessment of new clinically competitive trials. In this commentary we discuss how an optimized functional imaging protocol could assist new clinical trials using fetal cell transplantation in Parkinson's disease.
ACCESSION #
61012784

 

Related Articles

  • Next-generation active immunization approach for synucleinopathies: implications for Parkinson's disease clinical trials. Mandler, Markus; Valera, Elvira; Rockenstein, Edward; Weninger, Harald; Patrick, Christina; Adame, Anthony; Santic, Radmila; Meindl, Stefanie; Vigl, Benjamin; Smrzka, Oskar; Schneeberger, Achim; Mattner, Frank; Masliah, Eliezer // Acta Neuropathologica;Jun2014, Vol. 127 Issue 6, p861 

    Immunotherapeutic approaches are currently in the spotlight for their potential as disease-modifying treatments for neurodegenerative disorders. The discovery that α-synuclein (α-syn) can transmit from cell to cell in a prion-like fashion suggests that immunization might be a viable option...

  • Development of a Patient Questionnaire to facilitate recognition of motor and non-motor wearing-off in Parkinson’s disease. Stacy, M.; Hauser, R. // Journal of Neural Transmission;Feb2007, Vol. 114 Issue 2, p211 

    We previously reported that the use of a specifically designed Wearing-Off Questionnaire (WOQ) identified symptoms of wearing-off more frequently than standard assessments conducted by movement disorder specialists during a routine office visit. In the previous study we used a WOQ of 32...

  • Stereotyped behavior or punding in Parkinson's disease. Miwa, Hideto // Journal of Neurology;Sep2007, Vol. 254 Issue S5, p61 

    In patients with Parkinson's disease (PD) disabling repetitive behaviors (stereotyped behaviors or punding) sometimes appear during the course of the illness. Since similar behavioral disorders can be observed in amphetamine and cocaine abusers, excessive dopaminergic tone might have a prominent...

  • Research Highlights.  // Molecular Therapy;Jul2014, Vol. 22 Issue 7, p1234 

    The article presents information on several research studies on molecular therapy. According to a recent report in "Cell Reports," fetal dopamine cells transplanted into the brains of patients with Parkinson's disease survived and functioned for up to 14 years. Another study, published in the...

  • Review: Anticholinergic drugs improve motor function and disability in Parkinson disease.  // ACP Journal Club;Jan/Feb2004, Vol. 140 Issue 1, p15 

    This article focuses on a study regarding anticholinergics for symptomatic management of parkinson's disease (PD), published in the 2003 issue of the journal "Cochrane Database of Systematic Reviews." For this study the researchers selected studies if they were randomized controlled trials that...

  • Newron begins trial of safinamide in Parkinson's disease patients.  // PharmaWatch: CNS;October 2004, Vol. 3 Issue 10, p10 

    The article presents information about an Italian-based Newron Pharmaceuticals SpA, which has initiated an international clinical trial of its investigational product, safinamide, in 240 patients with Parkinson's disease. The placebo-controlled, 18-month, phase III trial will compare two dose...

  • Review: Anticholinergic drugs improve motor function and disability in Parkinson disease: COMMENTARY. Holloway, Robert; Frank, Sam // ACP Journal Club;Jan/Feb2004, Vol. 140 Issue 1, p15 

    This article focuses on a study regarding anticholinergics for symptomatic management of parkinson's disease (PD), published in the 2003 issue of the journal "Cochrane Database of Systematic Reviews." In the authors' opinion, the study reminds us that most of what we do in medicine is based on...

  • Promising trial results for Teva's Parkinson's drug.  // PharmaWatch: CNS;October 2004, Vol. 3 Issue 10, p9 

    The article presents information on promising trial results for Teva Neuroscience Inc.'s Parkinson's drug. Teva's Parkinson's disease treatment, Agilect, reduces tremor and improves motor function in patients when used as part of dopamine replacement therapy, according to newly released data...

  • Where do we stand in the treatment of Parkinson's disease? Mizuno, Yoshikuni // Journal of Neurology;Sep2007, Vol. 254 Issue S5, p13 

    This article reviews the current situation regarding the treatment of Parkinson's disease (PD). How to apply the various therapeutic options to treat PD appears to be internationally agreed, but the currently available treatment methods are said to be all symptomatic ones. However, some of these...

Share

Read the Article

Courtesy of THE LIBRARY OF VIRGINIA

Sorry, but this item is not currently available from your library.

Try another library?
Sign out of this library

Other Topics